These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36540927)

  • 61. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
    Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: a large multicenter study.
    Ferreira JC; Marques HH; Ferriani MP; Gormezano NW; Terreri MT; Pereira RM; Magalhães CS; Campos LM; Bugni V; Okuda EM; Marini R; Pileggi GS; Barbosa CM; Bonfá E; Silva CA
    Lupus; 2016 Jun; 25(7):754-9. PubMed ID: 26821966
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
    von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
    Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.
    Hunnicutt JN; Fairburn-Beech J; Georgiou ME; Richards A; Gregan YI; Quasny H; Chauhan D
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36450407
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
    Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
    Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
    Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
    J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina.
    Scolnik M; Scaglioni V; Pons-Estel GJ; Soriano ER
    Lupus; 2019 Aug; 28(9):1167-1173. PubMed ID: 31299882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
    Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single center in China.
    Zhao Y; Qi F; Bai J; Zhang N; Yang T; Sun W; Li X; Wei W
    Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 38011668
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
    Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
    Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
    Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
    Urowitz MB; Ohsfeldt RL; Wielage RC; Kelton KA; Asukai Y; Ramachandran S
    Ann Rheum Dis; 2019 Mar; 78(3):372-379. PubMed ID: 30610066
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset Systemic Lupus Erythematosus.
    Silva MF; Ferriani MP; Terreri MT; Pereira RM; Magalhães CS; Bonfá E; Campos LM; Okuda EM; Appenzeller S; Ferriani VP; Barbosa CM; Ramos VC; Lotufo S; Silva CA
    J Rheumatol; 2015 Dec; 42(12):2296-303. PubMed ID: 26568586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.